Serum androgen and gonadotropin levels decline after progestogen-induced withdrawal bleeding in oligomenorrheic women with or without polycystic ovaries.
OBJECTIVE
To examine the effect of short-term progestogen treatment on androgen, gonadotropin, and sex hormone-binding globulin (SHBG) levels in oligomenorrheic women.


METHODS
Comparative study of changes in hormonal parameters in patients with or without ultrasonographically diagnosed polycystic ovarian disease (PCOD).


METHODS
Open patient clinic of reproductive endocrinology at University Central Hospital of Turku, Finland.


METHODS
Seventy-five oligomenorrheic women with (n = 51) or without (n = 24) PCOD.


METHODS
Serum concentrations of testosterone (T), androstenedione (A), dehydroepiandrosterone sulfate, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and SHBG.


RESULTS
The levels of T, A, LH, and the LH:FSH ratios decreased significantly after oral treatment with medroxyprogesterone acetate (10 mg/d for 10 days) in non-PCOD women and in women with PCOD decreasing the frequencies of pathological laboratory findings, in particular elevated levels of LH:FSH ratio and A in PCOD women and of LH:FSH ratio in non-PCOD women. The levels of T, A, and LH as well as the LH:FSH ratio were significantly higher in women with PCOD. Obesity was associated with high free androgen indices, low LH:FSH ratios, and low concentrations of LH, A, and SHBG.


CONCLUSIONS
The serum samples for hormonal analyses used as an aid in diagnosing PCOD should be obtained without pretreatment with progestogen because it masks the biochemical findings of PCOD.
Anttila
L
L
Department of Obstetrics and Gynecology, Turku University Central Hospital, Finland.
Koskinen
P
P
Kaihola
H L
HL
Erkkola
R
R
Irjala
K
K
Ruutiainen
K
K
D000293:Adolescent; D000328:Adult; D000728:Androgens / Q000097:blood*; D005260:Female; D006065:Gonadotropins, Pituitary / Q000097:blood*; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects / Q000627:therapeutic use; D009839:Oligomenorrhea / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000150:complications; D012738:Sex Hormone-Binding Globulin / Q000032:analysis*; D013375:Substance Withdrawal Syndrome; D014592:Uterine Hemorrhage / Q000139:chemically induced
D000728:Androgens; D006065:Gonadotropins, Pituitary; D012738:Sex Hormone-Binding Globulin; D017258:Medroxyprogesterone Acetate